EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

we recently compiled a list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts. In this article, we will look at where Alkermes (NASDAQ:ALKS) ranks among the most undervalued ...

Alkermes plc (NASDAQ:ALKS) just released its annual report and things are looking bullish. It was overall a positive result, with revenues beating expectations by 3.4% to hit US$1.6b.

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our ...

View the latest Alkermes PLC (ALKS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Alkermes Price Performance. Spin-Off Research. Post-spin-off, Alkermes (RemainCo) will retain its focus on significant unmet needs within neuroscience and driving the growth of its proprietary ...

The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over ...

Alkermes expects that revenue for full-year 2021 will be between $1.1 billion and $1.17 billion. It anticipates GAAP loss per share of $0.53 to $0.78, with adjusted non-GAAP EPS between $0.37 and ...

Alkermes reported slightly weaker-than-expected Q1 results several weeks ago, and the stock quote is down close to -30% since February. The good news for investors is the company: (1) ...